| Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial R Stupp, S Taillibert, A Kanner, W Read, DM Steinberg, B Lhermitte, ... Jama 318 (23), 2306-2316, 2017 | 2504 | 2017 |
| Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas H Brem, S Piantadosi, PC Burger, M Walker, R Selker, NA Vick, K Black, ... The Lancet 345 (8956), 1008-1012, 1995 | 1771 | 1995 |
| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ... Science translational medicine 9 (399), eaaa0984, 2017 | 1741 | 2017 |
| A patient-derived glioblastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity F Jacob, RD Salinas, DY Zhang, PTT Nguyen, JG Schnoll, SZH Wong, ... Cell 180 (1), 188-204. e22, 2020 | 856 | 2020 |
| Tumor angiogenesis: a quantitative method for histologic grading S Brem, R Cotran, J Folkman Journal of the National Cancer Institute 48 (2), 347-356, 1972 | 671 | 1972 |
| Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End … FG Davis, S Freels, J Grutsch, S Barlas, S Brem Journal of neurosurgery 88 (1), 1-10, 1998 | 638 | 1998 |
| First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma LM Liau, K Ashkan, DD Tran, JL Campian, JE Trusheim, CS Cobbs, ... Journal of translational medicine 16, 1-9, 2018 | 601 | 2018 |
| A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme MR Rosenfeld, X Ye, JG Supko, S Desideri, SA Grossman, S Brem, ... Autophagy 10 (8), 1359-1368, 2014 | 545 | 2014 |
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant … EA Chiocca, KM Abbed, S Tatter, DN Louis, FH Hochberg, F Barker, ... Molecular Therapy 10 (5), 958-966, 2004 | 534 | 2004 |
| Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology LB Nabors, J Portnow, M Ahluwalia, J Baehring, H Brem, S Brem, ... Journal of the National Comprehensive Cancer Network 18 (11), 1537-1570, 2020 | 406 | 2020 |
| Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor SS Brem, D Zagzag, AM Tsanaclis, S Gately, MP Elkouby, SE Brien The American journal of pathology 137 (5), 1121, 1990 | 304 | 1990 |
| Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 … LM Liau, K Ashkan, S Brem, JL Campian, JE Trusheim, FM Iwamoto, ... JAMA oncology 9 (1), 112-121, 2023 | 284 | 2023 |
| Prolonged tumor dormancy by prevention of neovascularization in the vitreous S Brem, H Brem, J Folkman, D Finkelstein, A Patz Cancer research 36 (8), 2807-2812, 1976 | 278 | 1976 |
| Angiogenesis as a marker of preneoplastic lesions of the human breast SS Brem, HM Jensen, PM Gullino Cancer 41 (1), 239-244, 1978 | 272 | 1978 |
| Angiogenesis and cancer control: from concept to therapeutic trial S Brem Cancer Control 6 (5), 1-18, 1999 | 234 | 1999 |
| Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α Q Wang, Z He, M Huang, T Liu, Y Wang, H Xu, H Duan, P Ma, L Zhang, ... Nature communications 9 (1), 559, 2018 | 233 | 2018 |
| Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia SS Brem, PM Gullino, D Medina Science 195 (4281), 880-882, 1977 | 230 | 1977 |
| Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and … GA Soff, J Sanderowitz, S Gately, E Verrusio, I Weiss, S Brem, HC Kwaan The Journal of clinical investigation 96 (6), 2593-2600, 1995 | 213 | 1995 |
| Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase … S Takano, S Gately, ME Neville, WF Herblin, JL Gross, H Engelhard, ... Cancer research 54 (10), 2654-2660, 1994 | 192 | 1994 |
| Inhibition of angiogenesis by Aβ peptides D Paris, K Townsend, A Quadros, J Humphrey, J Sun, S Brem, ... Angiogenesis 7, 75-85, 2004 | 185 | 2004 |
Donald M. O'RourkeUniversity of PennsylvaniaEmail được xác minh tại uphs.upenn.edu
